Open-label randomised trial of Tolvaptan versus fluid restriction in hospitalised patients with moderate-severe hyponatraemia

Grant number: 2005300 | Funding period: 2021 - 2024



Low blood sodium level, known as hyponatraemia, is the most common electrolyte problem. It occurs in 15% of hospital patients, and can cause confusion, seizure and fatal brain swelling. Standard treatment for hyponatraemia is limiting oral fluid, but this is slow and not always effective. The drug tolvaptan works in mild hyponatraemia, but hasn't been formally tested in severe cases. We will compare benefits and risks of tolvaptan versus fluid restriction in patients with severe hyponatremia.

University of Melbourne Researchers